Valuation Provectus Biopharmaceuticals, Inc. OTC Bulletin Board
Stocks
PVCT
US74373P1084
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | - |
| 06-18 | Provectus Biopharmaceuticals, Inc. - Shareholder/Analyst Call | |
| 05-18 | Provectus Biopharmaceuticals reports oral pv-10 anti-tumor activity in preclinical bladder cancer study | RE |
Company Valuation: Provectus Biopharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 23.43 | 23.07 | 45.43 | 40.27 | 50.48 | 23.49 |
| Change | - | -1.55% | 96.93% | -11.35% | 25.33% | -53.46% |
| Enterprise Value (EV) 1 | 47.13 | 24.13 | 47.59 | 43.22 | 53.35 | 26.22 |
| Change | - | -48.8% | 97.24% | -9.18% | 23.43% | -50.85% |
| P/E | -3.44x | -4.05x | -12.8x | -13x | -10.6x | -4.33x |
| PBR | -0.77x | -5.48x | -7.27x | -5.29x | -8.45x | -3.72x |
| PEG | - | 0.2x | 0.3x | 1x | -0.2x | -0.3x |
| Capitalization / Revenue | - | - | 45,934,892x | 72,213,378x | 81,789,566x | 69,899,095x |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -10x | -5.21x | -14.1x | -17.4x | -13.5x | -5.41x |
| EV / EBIT | -9.55x | -5.2x | -14x | -17.3x | -13.5x | -5.41x |
| EV / FCF | 44.5x | -3.48x | -39.6x | -37.2x | -18.2x | -19.6x |
| FCF Yield | 2.25% | -28.8% | -2.53% | -2.68% | -5.5% | -5.1% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.017 | -0.0136 | -0.008474 | -0.007393 | -0.0113 | -0.0129 |
| Distribution rate | - | - | - | - | - | - |
| Net sales | - | - | 0.989 | 0.5577 | 0.6171 | 0.3361 |
| EBITDA 1 | -4.694 | -4.628 | -3.38 | -2.489 | -3.939 | -4.842 |
| EBIT 1 | -4.936 | -4.641 | -3.391 | -2.498 | -3.946 | -4.844 |
| Net income 1 | -6.678 | -5.54 | -3.555 | -3.102 | -4.762 | -5.431 |
| Net Debt 1 | 23.7 | 1.061 | 2.163 | 2.95 | 2.877 | 2.727 |
| Reference price 2 | 0.0584 | 0.0550 | 0.1083 | 0.0960 | 0.1201 | 0.0559 |
| Nbr of stocks (in thousands) | 401,232 | 419,447 | 419,497 | 419,522 | 420,280 | 420,280 |
| Announcement Date | 3/2/21 | 3/29/22 | 3/30/23 | 3/28/24 | 3/28/25 | 3/26/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.64x | 8.1x | 25.37x | 0.06% | 52.88B | |
| 19.32x | 5.85x | 12.69x | 1.56% | 50.98B | |
| -18.03x | 4.26x | -7.44x | -.--% | 22.81B | |
| -39.18x | 12.95x | -37.77x | -.--% | 22.43B | |
| 21.24x | 4.14x | 10.76x | -.--% | 17.01B | |
| 22.41x | 4.49x | 14.87x | -.--% | 15.91B | |
| 16.69x | 4.82x | 11.31x | -.--% | 13.29B | |
| 44.65x | 16.94x | 51.24x | -.--% | 13.58B | |
| -74.21x | 7.51x | -67.3x | -.--% | 11.75B | |
| Average | 2.84x | 7.67x | 1.53x | 0.18% | 24.52B | |
| Weighted average by Cap. | 9.49x | 7.42x | 6.56x | 0.37% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- PVCT Stock
- PVCT Stock
- Valuation Provectus Biopharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
